Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
New Triple-Threat cancer treatment enters human testing
Disease control OngoingThis early-stage trial is testing whether a new experimental drug called RO7496353 is safe and effective when combined with existing immunotherapy and chemotherapy. The study involves 102 people with advanced lung, stomach, or pancreatic cancers that have spread and are considere…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:46 UTC
-
Two-year safety check for SMA drug in hundreds of patients
Disease control OngoingThis study follows 404 adults and children with spinal muscular atrophy (SMA) who are already taking the approved drug risdiplam (Evrysdi). Researchers will track patients for about two years to monitor the long-term safety of the medication and see how well it continues to work.…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New cancer pill targets specific gene fault in advanced tumors
Disease control OngoingThis early-stage study is testing the safety and dosing of an experimental pill called inavolisib. It is for people with advanced breast cancer or other solid tumors that have a specific genetic change called a PIK3CA mutation. The study will give the pill alone or in combination…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First human test of Vision-Saving eye injection begins
Disease control OngoingThis is an early-stage study to check the safety and side effects of a new drug called RO7497372, given as an injection into the eye, for people with diabetic macular edema (DME). The study has two parts: first to find safe dose levels, and second to test two selected doses more …
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for advanced breast cancer patients after standard treatment fails
Disease control OngoingThis study is testing whether a new drug called giredestrant, when combined with everolimus, works better than current standard hormone therapies combined with everolimus for people with advanced breast cancer. It's for patients whose cancer has grown despite previous treatment w…
Phase: PHASE3 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug combo tested for Tough-to-Treat skin cancer
Disease control OngoingThis early-stage study is testing a new drug called belvarafenib, both by itself and in combination with other cancer drugs, for people with advanced melanoma that has a specific genetic change (NRAS mutation) and has stopped responding to standard immunotherapy. The main goals a…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug duo tested for Tough-to-Treat blood cancer
Disease control OngoingThis early-stage study is testing whether two new drugs, XmAb24306 and cevostamab, can be safely given together to people with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial will enroll about 90 patients who have already tried at …
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New cancer drug enters first human trials
Disease control OngoingThis is an early-stage study to check the safety and side effects of a new drug called XmAb24306. It will be tested alone and in combination with an existing immunotherapy drug (atezolizumab) in about 195 adults with advanced solid tumors that have spread or cannot be cured by su…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo tested for tough-to-treat cancers
Disease control OngoingThis early-stage study is testing the safety and dosing of a new drug called runimotamab. It is being given alone and in combination with an existing cancer drug, trastuzumab, to people with advanced HER2-positive cancers like breast or stomach cancer that have stopped responding…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New leukemia combo aims to stop treatment for years
Disease control OngoingThis study is testing if adding a drug called venetoclax to a standard first-line treatment (a BTK inhibitor) can lead to a very deep and lasting remission in people with chronic lymphocytic leukemia (CLL). The goal is to get the cancer down to such low levels that patients might…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Cancer patients get chance to continue promising treatment in safety study
Disease control OngoingThis study allows patients with metastatic breast cancer who were benefiting from the drug trastuzumab emtansine in previous trials to continue receiving it. The main goal is to monitor long-term safety and side effects while patients keep getting treatment. The study includes 72…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New hope for advanced breast cancer: early trial tests experimental drug combinations
Disease control OngoingThis early-stage trial is testing the safety and appropriate dosing of an experimental drug called GDC-9545 for advanced breast cancer. The study involves 181 patients with estrogen receptor-positive breast cancer that has spread or returned. Researchers are testing GDC-9545 alon…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC
-
Eye drug trial focuses on underrepresented diabetic patients
Disease control OngoingThis study is testing how well the eye injection faricimab works and how safe it is for people with diabetic macular edema (DME), a swelling in the back of the eye that can cause vision loss. It focuses on enrolling adults from racial and ethnic groups that are often underreprese…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
New drug targets 'Undruggable' cancer mutation in early human trial
Disease control OngoingThis is an early-stage study to find a safe dose and see how the body processes a new drug called GDC-6036. It is being tested alone and with other cancer drugs in people with advanced solid tumors, like lung or colorectal cancer, that have a specific genetic change called KRAS G…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control OngoingThis early-stage trial is testing a new drug called cevostamab, both by itself and in combination with other approved myeloma medications. It aims to find safe doses and see if these treatments can help control multiple myeloma that has returned or stopped responding to other the…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
New shot offers hope for Hard-to-Treat lymphomas
Disease control OngoingThis study is testing a new, more convenient under-the-skin injection of an immunotherapy drug called mosunetuzumab for people with certain types of B-cell lymphoma. It aims to see if this method is safe, effective, and how the body handles the drug. The trial includes people wit…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC
-
Scientists track eye disease progression in 400 patients
Knowledge-focused OngoingThis study aims to better understand how intermediate age-related macular degeneration (AMD) worsens over time. Researchers will follow 400 participants with early-stage AMD for about 3 years, tracking how quickly their vision changes and measuring specific eye structures. The go…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC